drugset
drugset / Trial / NCT00004241

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma

NCT00004241 ↗

Phase 1 Completed 60 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with advanced epithelial cancer, malignant lymphoma, or sarcoma

Timeline

Start
1999-10
Primary completion
2006-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject tanespimycin Unknown — Intravenous

Indications

AIDS-related primary central nervous system lymphoma Burkitt lymphoma Ewing sarcoma/peripheral primitive neuroectodermal tumor Hodgkins lymphoma MALT lymphoma adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma cancer of unknown primary site central nervous system non-hodgkin lymphoma chondrosarcoma chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma immunodeficiency-associated lymphoproliferative disease intraocular lymphoma large-cell immunoblastic lymphoma mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma osteosarcoma ovarian sarcoma small intestine lymphoma splenic marginal zone lymphoma uterine corpus sarcoma